This post was originally published on here
Biomedical scientists are racing to identify the genes that contribute to illness, hoping that these discoveries will lead to treatments that target the right genes and help bring the body back to health.
When one faulty gene is responsible, the path to understanding the problem can be fairly direct. Many conditions, however, are far more complicated. In these cases, multiple genes, sometimes even thousands, play a role, and it becomes much harder to sort out how they connect to the disease.
A new genomic mapping approach could make that challenge easier to tackle. In a Nature study, researchers at Gladstone Institutes and Stanford University used a broad strategy that tests the impact of every gene in a cell, linking diseases and other traits to the underlying genetic systems that shape them. The resulting maps could cut through confusing biology and spotlight the genes most likely to be useful targets for new therapies.
“We can now look across every gene in the genome and get a sense of how each one affects a particular cell type,” says Gladstone Senior Investigator Alex Marson, MD, PhD, the Connie and Bob Lurie Director of the Gladstone-UCSF Institute of Genomic Immunology, who co-led the study. “Our goal is to use this information as a map to gain new insights into how certain genes influence specific traits.”
Finding the ‘Why’ Behind Genetic Risk
For years, scientists have relied heavily on “genome-wide association studies,” which scan the DNA of thousands of people to find statistical links between genetic differences and traits, including disease risk. These efforts have generated enormous datasets, but turning those signals into clear biological explanations can be difficult, especially for traits influenced by many genes.
“Even with these studies, there remains a huge gap in understanding disease biology on a genetic level,” says first author Mineto Ota, MD, PhD. Ota is a postdoctoral scholar in Marson’s Gladstone lab, as well as in the lab of Stanford scientist Jonathan Pritchard, PhD. “We understand that many variants are associated with disease; we just don’t understand why.”
Mineto compares it to having a map with a clear starting point and endpoint, but no routes connecting the two.
“To understand complex traits, we really need to focus on the network,” says Pritchard, a professor of Biology and Genetics at Stanford, who co-led the study with Marson. “How do we think about biology when thousands and thousands of genes, with many different functions, are all affecting a trait?”
Combining Cell Experiments With Big Population Data
To dig into that network problem, the researchers pulled information from two databases.
One dataset came from a human leukemia cell line that is commonly used to study red blood cell traits. In earlier work, an MIT researcher who was not involved in this study had switched off each gene in that cell line, one at a time, and tracked how losing that gene changed genetic activity.
Marson’s team then paired those results with UK Biobank data, which includes genomic sequences from more than 500,000 people. Ota searched for individuals with genetic mutations that lowered gene function in ways that changed their red blood cells.
Putting the two sources together allowed the researchers to build a detailed map of the gene networks that influence red blood cell traits. The picture that emerged showed a remarkably complex genetic landscape. With this approach, they could see the starting point, the destination, and the intricate set of connections in between.
They also discovered that some genes affect several biological processes at the same time, weakening certain activities while increasing others. One example is SUPT5H, a gene associated with beta thalassemia, a blood disorder that disrupts hemoglobin production and can lead to moderate to severe anemia. The researchers connected SUPT5H to three key blood cell programs: hemoglobin production, cell cycle, and autophagy. They also showed how the gene influences each program, either increasing or reducing gene activity.
“SUPT5H regulates all three main pathways that affect hemoglobin,” Pritchard says. “It activates hemoglobin synthesis, slows down the cell cycle, and slows down autophagy, which together have a synergistic effect.”
Why This Mapping Method Could Matter for Immunology
Being able to reveal the detailed genetic pathways that control how cells function could reshape both basic biology and drug development.
Although the team identified multiple ways gene networks shape blood cell behavior, the bigger story is the tool itself. The research group, and potentially many other scientists, can now apply the same strategy to other human cell types to uncover the molecular patterns that drive disease.
For the Marson lab, which focuses on T cells and other parts of the immune system, the method could open the door to many more discoveries.
“The genetic burden associated with many autoimmune diseases, immune deficiencies, and allergies are overwhelmingly linked to T cells,” Marson says. “We look forward to developing additional detailed maps that will help us really understand the genetic architecture behind these immune-mediated diseases.”
The study, “Causal modeling of gene effects from regulators to programs to traits,” appears in the December 10, 2025 issue of Nature. Authors include: Mineto Ota, Jeffrey Spence, Tony Zeng, Emma Dann, Nikhil Milind, Alexander Marson, and Jonathan Pritchard. This research was funded by the National Institutes of Health, the Simons Foundation, the Lloyd J. Old STAR Award, the Parker Institute for Cancer Immunotherapy, the Innovative Genomics Institute, the Larry L. Hillblom Foundation, the Northern California JDRF Center of Excellence, the Byers family, K. Jordan, the CRISPR Cures for Cancer Initiative, the Astellas Foundation for Research on Metabolic Disorders, the Chugai Foundation for Innovative Drug Discovery Science, and the EMBO Postdoctoral Fellowship.
